We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 23 juni 2017

The Lancet: [News] NICE recommends routine NHS funding for Kadcyla

[News] NICE recommends routine NHS funding for Kadcyla
Following a cost-effectiveness analysis, the UK National Institute for Health and Care Excellence (NICE) has recommended that the breast cancer drug Kadcyla (trastuzumab emtansine) should be routinely funded by the UK National Health Service (NHS).
Read more

[News] Risk prediction equations for survival in colorectal cancer
Researchers have developed risk prediction equations to estimate survival for patients with colorectal cancer. Julia Hippisley-Cox and Carol Coupland (University of Nottingham, UK) obtained data for 44 145 individuals aged 15–99 years with colorectal cancer from the QResearch database, which provides detailed information about patients from UK general practices and is linked to the national cancer registry. They created a risk calculator for all-cause mortality (primary outcome) and cancer-specific mortality (secondary outcome) using information from both databases.
Read more

[News] Potential drug targets in small-bowel adenocarcinoma
Most small-bowel adenocarcinomas have genomic alterations that are potentially targetable, according to findings from a recent genomic profiling study. Currently, few treatment options exist for this rare malignancy, which has a median overall survival of 20 months, and until now it has not undergone a comprehensive genomic analysis.
Read more

[Articles] Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be recommended in this setting.
Read more

[Comment] Quality of life after nivolumab treatment for head and neck cancer
When evaluating the effect of a new drug, it is important not only to take clinical outcomes such as overall survival, the proportions of patients achieving an overall response, and safety into account, but also the patients' experience with it. Only by considering clinical and patient-reported outcomes (PRO) together can the overall benefit of a treatment be judged. For that reason, it is crucial to report the PROs results together or shortly after the publication of the clinical outcomes. In previous times, this has unfortunately often been neglected, and the PROs have been published years after the main paper came out.
Read more